Comprehensive Review on Drug-target Interaction Prediction - Latest Developments and Overview

Overview

Journal Curr Drug Discov Technol

Publisher Bentham Science Publishers

Date 2023 Sep 8

PMID 37680152

Authors

Ali K Abdul Raheem

Ban N Dhannoon

Affiliations

Soon will be listed here.

Abstract

Drug-target interactions (DTIs) are an important part of the drug development process. When the drug (a chemical molecule) binds to a target (proteins or nucleic acids), it modulates the biological behavior/function of the target, returning it to its normal state. Predicting DTIs plays a vital role in the drug discovery (DD) process as it has the potential to enhance efficiency and reduce costs. However, DTI prediction poses significant challenges and expenses due to the time-consuming and costly nature of experimental assays. As a result, researchers have increased their efforts to identify the association between medications and targets in the hopes of speeding up drug development and shortening the time to market. This paper provides a detailed discussion of the initial stage in drug discovery, namely drug-target interactions. It focuses on exploring the application of machine learning methods within this step. Additionally, we aim to conduct a comprehensive review of relevant papers and databases utilized in this field. Drug target interaction prediction covers a wide range of applications: drug discovery, prediction of adverse effects and drug repositioning. The prediction of drugtarget interactions can be categorized into three main computational methods: docking simulation approaches, ligand-based methods, and machine-learning techniques.

Citing Articles

MCF-DTI: Multi-Scale Convolutional Local-Global Feature Fusion for Drug-Target Interaction Prediction.

Wang J, He R, Wang X, Li H, Lu Y Molecules. 2025; 30(2).

PMID: 39860144 PMC: 11767603. DOI: 10.3390/molecules30020274.

References

Varnek A, Baskin I . Chemoinformatics as a Theoretical Chemistry Discipline. Mol Inform. 2016; 30(1):20-32. DOI: 10.1002/minf.201000100. View

Kapetanovic I . Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact. 2007; 171(2):165-76. PMC: 2253724. DOI: 10.1016/j.cbi.2006.12.006. View

Patel L, Shukla T, Huang X, Ussery D, Wang S . Machine Learning Methods in Drug Discovery. Molecules. 2020; 25(22). PMC: 7696134. DOI: 10.3390/molecules25225277. View

Helleboid S, Haug C, Lamottke K, Zhou Y, Wei J, Daix S . The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1). J Biomol Screen. 2013; 19(3):399-406. DOI: 10.1177/1087057113497095. View

Klebe G . Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today. 2006; 11(13-14):580-94. PMC: 7108249. DOI: 10.1016/j.drudis.2006.05.012. View

Dickson M, Gagnon J . Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004; 3(5):417-29. DOI: 10.1038/nrd1382. View

Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3):203-14. DOI: 10.1038/nrd3078. View

Sachdev K, Gupta M . A comprehensive review of feature based methods for drug target interaction prediction. J Biomed Inform. 2019; 93:103159. DOI: 10.1016/j.jbi.2019.103159. View

Pliakos K, Vens C . Drug-target interaction prediction with tree-ensemble learning and output space reconstruction. BMC Bioinformatics. 2020; 21(1):49. PMC: 7006075. DOI: 10.1186/s12859-020-3379-z. View

10.

Wang L, You Z, Chen X, Xia S, Liu F, Yan X . A Computational-Based Method for Predicting Drug-Target Interactions by Using Stacked Autoencoder Deep Neural Network. J Comput Biol. 2017; 25(3):361-373. DOI: 10.1089/cmb.2017.0135. View

11.

Beck B, Shin B, Choi Y, Park S, Kang K . Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020; 18:784-790. PMC: 7118541. DOI: 10.1016/j.csbj.2020.03.025. View

12.

Nguyen T, Le H, Quinn T, Nguyen T, Le T, Venkatesh S . GraphDTA: predicting drug-target binding affinity with graph neural networks. Bioinformatics. 2020; 37(8):1140-1147. DOI: 10.1093/bioinformatics/btaa921. View

13.

Ezzat A, Wu M, Li X, Kwoh C . Computational prediction of drug-target interactions using chemogenomic approaches: an empirical survey. Brief Bioinform. 2018; 20(4):1337-1357. DOI: 10.1093/bib/bby002. View

14.

Dudley J, Deshpande T, Butte A . Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform. 2011; 12(4):303-11. PMC: 3137933. DOI: 10.1093/bib/bbr013. View

15.

Lounkine E, Keiser M, Whitebread S, Mikhailov D, Hamon J, Jenkins J . Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012; 486(7403):361-7. PMC: 3383642. DOI: 10.1038/nature11159. View

16.

Yao L, Evans J, Rzhetsky A . Novel opportunities for computational biology and sociology in drug discovery. Trends Biotechnol. 2010; 28(4):161-70. PMC: 3654551. DOI: 10.1016/j.tibtech.2010.01.004. View

17.

Chen H, Zhang Z . A semi-supervised method for drug-target interaction prediction with consistency in networks. PLoS One. 2013; 8(5):e62975. PMC: 3646965. DOI: 10.1371/journal.pone.0062975. View

18.

Frolov A, Chahwan S, Ochs M, Arnoletti J, Pan Z, Favorova O . Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther. 2003; 2(8):699-709. View

19.

Giacomini K, Krauss R, Roden D, Eichelbaum M, Hayden M, Nakamura Y . When good drugs go bad. Nature. 2007; 446(7139):975-7. DOI: 10.1038/446975a. View

20.

Pauwels E, Stoven V, Yamanishi Y . Predicting drug side-effect profiles: a chemical fragment-based approach. BMC Bioinformatics. 2011; 12:169. PMC: 3125260. DOI: 10.1186/1471-2105-12-169. View